Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Diartis Pharmaceuticals
AddedFeb 18, 2024
UpdatedJun 18, 2026
Diartis Pharmaceuticals

Diartis Pharmaceuticals

Acquired

Diartis Pharmaceuticals, a biopharmaceutical firm, focuses on developing novel proteins for metabolic disorders.

HQ
Mountain View, CA, US
Founded
2010
Overview
Compare
Employees

Diartis Pharmaceuticals, headquartered in Mountain View, CA, is a biopharmaceutical company dedicated to developing novel therapeutic proteins for treating metabolic disorders. Formed in December 2010, the company acquired the VRS-859 program from Versartis, Inc., enhancing its focus on innovative metabolic treatments.

Diartis Pharmaceuticals has made significant strides in the biopharmaceutical industry by advancing the VRS-859 program. Their work aims to address unmet medical needs in metabolic health, contributing to improved patient outcomes and advancing therapeutic options in the field.

Diartis Pharmaceuticals - Similar Companies

KinDex Pharmaceuticals logo

KinDex Pharmaceuticals

NuSirt Sciences logo

NuSirt Sciences

nusirt.com

Arisaph Pharmaceuticals logo

Arisaph Pharmaceuticals

Aria Pharmaceuticals logo

Aria Pharmaceuticals

Artizan Biosciences logo

Artizan Biosciences

Vitreoretinal Technologies logo

Vitreoretinal Technologies

Attune Pharmaceuticals logo

Attune Pharmaceuticals

Thetis Pharmaceuticals logo

Thetis Pharmaceuticals

thetispharma.com

Argentis Pharmaceuticals logo

Argentis Pharmaceuticals

argentisrx.com

NephroDI Therapeutics logo

NephroDI Therapeutics

nephrodi.com

Theracos logo

Theracos

theracos.com

Pharmatrophix logo

Pharmatrophix

pharmatrophix.com

Energesis Pharmaceuticals logo

Energesis Pharmaceuticals

Response Pharmaceuticals logo

Response Pharmaceuticals

Arthrosi Therapeutics logo

Arthrosi Therapeutics

arthrosi.com

Diartis Pharmaceuticals - Quick Facts

Who are Diartis Pharmaceuticals' competitors?

Companies similar to Diartis Pharmaceuticals include KinDex Pharmaceuticals, NuSirt Sciences, Arisaph Pharmaceuticals and Aria Pharmaceuticals.

When was Diartis Pharmaceuticals founded?

Diartis Pharmaceuticals was founded in 2010.

Where is Diartis Pharmaceuticals' headquarters located?

Diartis Pharmaceuticals' headquarters is located in Mountain View, CA, US.

Diartis Pharmaceuticals - Classification

Ownership
  • Private
Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Therapeutic Proteins
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 325000Chemical Manufacturing
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 2830Drugs
  • 2834Pharmaceutical Preparations
Show 13 more industry codes
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 620000Health Care and Social Assistance
  • 541000Professional, Scientific, and Technical Services
  • 623000Nursing and Residential Care Facilities
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8000Health Services
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8730Research, Development, And Testing Services
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
  • 8731Commercial Physical and Biological Research